Publication at Faculty of Medicine in Pilsen |
2017
Abstract
Treatment of hypercholesterolaemia belongs to one of the most important approaches in primary and secondary cardiovascular prevention. Statin monotherapy is often insufficient thus the combination of ezetimibe and atorvastatin (Zoletorv 10mg/20mg or Zoletorv 10mg/40mg) could improve this situation.
Atorvastatin reduces the cholesterol synthesis and ezetimibe blocks the cholesterol reabsorption from the small bowel. Combination of statin and ezetimibe is more effective than statin monotherapy and also significantly reduces cardiovascular risk (IMPROVE-IT study).
This combination is safe and well tolerated and it could contribute to the improvement of dyslipidemia treatment results and to cardiovascular risk reduction.